Tempus AI reported a significant improvement in its profitability trajectory for 2025, primarily driven by growth in the Diagnostics segment, with Q4 gross profit increasing 94.7% year-over-year. The company reached an adjusted EBITDA of $12.9 million for the quarter and projects approximately $65 million for 2026, which reflects ongoing scale benefits and improved operational discipline.
Despite these gains, Tempus continues to report GAAP net losses of $54.2 million due to high stock-based compensation and other non-cash expenses. The company’s revenue and adjusted EBITDA guidance indicates a focus away from achieving immediate GAAP profitability, as substantial GAAP losses could affect its valuation based on long-term operating leverage rather than short-term earnings.
Meanwhile, Hims & Hers Health, Inc. reported fourth-quarter 2025 revenues of nearly $617.8 million, achieving positive net income amid ongoing strategic investments. GoodRx Holdings, Inc. maintains stable revenues while pivoting toward higher-margin solutions, aiming for sustained margin growth despite challenges in prescription transaction volumes.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
